Johnson & Johnson stock ticks up on lupus drug data as earnings loom
New York, January 6, 2026, 12:58 EST — Regular session Johnson & Johnson shares rose on Tuesday after the company reported positive mid-stage data for its experimental lupus drug nipocalimab and outlined plans for late-stage testing. The stock was up $1.10, or 0.5%, at $205.41 in midday New York trading.